Halix B.V., a contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of complex therapeutic antibodies (proteins) and viral products, has appointed Dr. Lutz Hilbrich as its new Chief Executive Officer (CEO), effective immediately.
 
With over 20 years in the biotechnology and pharmaceutical sectors, Hilbrich brings extensive experience in strategic leadership, operational excellence, and innovation in biopharmaceutical development and manufacturing. He succeeds Alex Huybens, who has successfully built and led Halix’s activities in recent years.
 
“I am honored to join Halix at such an exciting time in the company’s journey,” said Hilbrich, who has worked across multiple regions, including the US, China, Europe, and Africa, in both big pharma and mid-sized companies. “Healthcare is a human right and as a Physician and Senior Biotech Executive, I am committed to relentlessly contributing to shaping the future of medicine by enabling our global partners to develop and manufacture life-saving therapies. Halix has established itself as a trusted partner for the development and manufacturing of bio-pharmaceutical products, and I am eager to work with the talented team at Halix to build on this strong foundation.”
 
“We are thrilled to welcome Dr. Lutz Hilbrich as our new CEO,” said Dr. Harry Flore, Chairman of the Supervisory Board. “His extensive experience and his proven track record in the field of biosimilars, cell & gene therapy as well as vaccines, position him well to lead Halix into its next phase of growth.”